Mirati Therapeutics

New phase 3 trial NCT06875310 posted by Mirati Therapeutics Inc.: "A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)". New trial on a phase 3 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 7 days ago.

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.

New phase 2_3 trial NCT04613596 posted by Mirati Therapeutics Inc.: "Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7". New trial on a phase 2_3 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 14 days ago.

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

New phase 2 trial NCT07415031 posted by Mirati Therapeutics Inc.: "A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies". New trial on a phase 2 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 21 days ago.

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.